SAVIMS

SAVIMS logo white
Menu

COVID-19

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Summary of Pfizer-BioNTech COVID-19 Vaccine EUA Briefing Document

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: U.S. Food and Drug Administration. (2020). Vaccines and related biological products advisory committee meeting December 10, 2020 FDA briefing document Pfizer-BioNTech COVID-19 vaccine. https://www.fda.gov/media/144246/download Summary: On December 10, 2020, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviewed Pfizer-BioNTech’s COVID-19 vaccine, BNT162b2, which received an Emergency Use Authorization (EUA) request on November 20, […]

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Understanding Efficacy and Effectiveness of Vaccines

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Joi, P. (2020). What is the difference between efficacy and effectiveness? Gavi, the Vaccine Alliance. Retrieved from https://www.gavi.org/vaccineswork/what-difference-between-efficacy-and-effectiveness Summary: Efficacy and effectiveness are two crucial terms in vaccine science, often conflated but distinct. Efficacy refers to the performance of a vaccine under ideal, controlled conditions, typically demonstrated in clinical trials where a vaccinated group

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Monitoring COVID-19 Vaccine Safety: FDA’s Comprehensive Plan

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Anderson, S. (2020). CBER plans for monitoring COVID-19 vaccine safety and effectiveness. Vaccines and Related Biological Products Advisory Committee Meeting, FDA. Summary: The FDA’s Centre for Biologics Evaluation and Research (CBER) presented its comprehensive strategy for monitoring the safety and effectiveness of COVID-19 vaccines during the VRBPAC meeting on October 22, 2020. The approach

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Phase 3 Clinical Trial of COVID-19 Vaccine Initiated

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: National Institutes of Health. (2020, July 27). Phase 3 clinical trial of investigational vaccine for COVID-19 begins. https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins Summary: The National Institutes of Health (NIH) has commenced a Phase 3 clinical trial to assess the efficacy of the investigational mRNA-1273 vaccine, co-developed by Moderna, Inc. and NIH’s National Institute of Allergy and Infectious Diseases

COVID-19, Ethics, Other repurposed substances, Peer-reviewed evidence, Reference Library, Resource Type, Treatment, Viral illnesses

The Retraction of a Controversial Study on COVID-19 Treatments

| | COVID-19, Ethics, Other repurposed substances, Peer-reviewed evidence, Reference Library, Resource Type, Treatment, Viral illnesses

Reference: Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020). Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. The Lancet, published online May 22, https://doi.org/10.1016/S0140-6736(20)31180-6 Summary: In June 2020, The Lancet announced the retraction of a significant study assessing the effectiveness of hydroxychloroquine

COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Guidance on COVID-19 Vaccine Development

| | COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: U.S. Department of Health and Human Services. (2020). Contains nonbinding recommendations: Development and licensure of vaccines to prevent COVID-19 guidance for industry. Food and Drug Administration. Summary: In June 2020, the U.S. Food and Drug Administration (FDA) issued guidance to assist the development and licensure of COVID-19 vaccines amidst the public health emergency. This

COVID-19, Ethics, Other repurposed substances, Peer-reviewed evidence, Reference Library, Resource Type, Treatment, Viral illnesses

Hydroxychloroquine and Chloroquine in COVID-19 Treatment: A Multinational Analysis

| | COVID-19, Ethics, Other repurposed substances, Peer-reviewed evidence, Reference Library, Resource Type, Treatment, Viral illnesses

Reference: Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020). Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. The Lancet, 395(10240), 1820-1830. https://doi.org/10.1016/S0140-6736(20)31180-6 Summary: The study evaluates the efficacy of hydroxychloroquine and chloroquine, either alone or in combination with macrolides, in treating COVID-19

COVID-19, Other repurposed substances, Other scientific evidence, Other viral illnesses, Resource Type, Treatment, Viral illnesses

An Effective At-Home Treatment for Viral Infections

| | COVID-19, Other repurposed substances, Other scientific evidence, Other viral illnesses, Resource Type, Treatment, Viral illnesses

Reference: Levy, T. E. (2020). An at-home treatment that can cure any virus, including coronavirus. Retrieved from www.PeakEnergy.com Summary: The article discusses a simple and inexpensive treatment for viral infections, including COVID-19, using 3% hydrogen peroxide. Originally conceptualised by Dr. Charles Farr, this therapy targets infected cells rather than the viruses themselves, which cannot be

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Safety and Efficacy of BNT162 RNA-Based COVID-19 Vaccines

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Pfizer. (2020). PF-07302048 (BNT162 RNA-Based COVID-19 vaccines) protocol C4591001. Summary: The document outlines the Phase 1/2/3 clinical trial to evaluate the safety, tolerability, immunogenicity, and efficacy of BNT162 RNA-based COVID-19 vaccines, developed by Pfizer and BioNTech. The trial investigates two vaccine candidates: BNT162b1, encoding the receptor-binding domain (RBD), and BNT162b2, encoding the prefusion spike

COVID-19, Ivermectin, Other viral illnesses, Peer-reviewed evidence, Resource Type, Treatment, Viral illnesses

Ivermectin: A Multifaceted Wonder Drug

| | COVID-19, Ivermectin, Other viral illnesses, Peer-reviewed evidence, Resource Type, Treatment, Viral illnesses

Reference: Crump, A. (2017). Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations. The Journal of Antibiotics, 70(6), 495-505. https://doi.org/10.1038/ja.2017.11 Summary: Over the last decae, ivermectin has gained recognition for its significant contributions to global health. Discovered from a soil microbe in Japan, it was developed by Satoshi Ōmura and William Campbell, who

Scroll to Top